Renal protection by antihypertensive therapy

Area of Science:

• Nephrology
• Cardiology
• Hypertension Management

Background:

• Adequate renal protection necessitates strict blood pressure control and minimizing proteinuria/microalbuminuria.
• Previously, it was assumed blood pressure control alone would suffice for reducing proteinuria.

Purpose of the Study:

• To confirm the necessity of combination therapy for renal protection in hypertensive patients.
• To evaluate the efficacy of specific drug classes in reducing proteinuria and protecting kidneys.

Main Methods:

• Review of recent data on renal protection strategies in hypertensive patients (diabetic and non-diabetic).
• Analysis of combination therapy regimens involving angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).
• Assessment of the role of calcium channel blockers and diuretics in conjunction with ACEIs/ARBs.

Main Results:

• Renal protection in hypertensive patients requires combination therapy, not solely blood pressure control.
• Combination therapy including ACEIs or ARBs, potentially with calcium channel blockers and diuretics, effectively reduces proteinuria.
• Up-titration of drugs blocking angiotensin II effects enhances proteinuria reduction.

Conclusions:

• Combination therapy is essential for adequate renal protection in hypertensive individuals.
• Targeting the renin-angiotensin system with ACEIs or ARBs is key, supplemented by other agents and risk factor management.
• Managing associated risks like smoking and dyslipidemia is vital for comprehensive kidney protection.